Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details Textual)

v3.19.1
Organization, Plan of Business Operations (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
Feb. 08, 2019
Nov. 12, 2018
Mar. 31, 2019
Dec. 31, 2018
Retained Earnings (Accumulated Deficit)     $ (53,478) $ (42,209)
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 31,500      
Business Acquisition, Share Price $ 6.00      
Line of Credit [Member]        
Interim Financing Amount   $ 7,000    
Invagen Pharmaceuticals Inc [Member]        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 31,500 215,000    
Business Acquisition, Share Price $ 6.00      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%      
Invagen Pharmaceuticals Inc [Member] | Common Stock [Member]        
Stock Issued During Period, Value, Acquisitions   $ 180,000